Dr Patrick Bowden is committed to providing comprehensive, patient focused cancer care. He is a highly experienced doctor, staying at the forefront of cutting-edge radiation therapy techniques and clinical research.
Dr Patrick Bowden has 20 years’ experience as a consultant radiation oncologist and is based at Icon Cancer Centre Richmond, Freemasons, Moreland, Mulgrave and Canberra. He has continually been at the forefront of new technologies in radiation therapy treatment throughout his oncology career. Dr Bowden is a leading specialist in the use of intensity modulated radiation therapy [IMRT] and stereotactic radiation therapy for treatment of early metastatic disease.
After establishing his radiation oncology career at Peter MacCallum Cancer Centre, he became director of the Tattersall’s Cancer Centre in 2007, the private arm of the Peter MacCallum . In 2011, he was appointed as the inaugural Director of Epworth Radiation Oncology. In this role, he built Australia’s largest stereotactic radiation therapy service, incorporated a clinical trial institute and integrated oncology services at Epworth Freemasons. In 2016, the South West Regional Cancer Centre in Warrnambool was established under his directorship, before his integral role in the transition of Epworth Radiation Oncology to Icon Cancer Centre.
Dr Bowden is actively involved in education, medical leadership, research and clinical trials. He was previously a member of Epworth Medical Advisory Committee from 2007-2016 (maximum allowed 9 year tenure). Outside radiation oncology, he is the Chairman of Access Telehealth; Australia’s largest provider of free consultations to patients in rural and remote areas.
Dr Bowden has been active in numerous clinical trials and acted as a Principal Investigator in key studies investigating radiation therapy treatments for lung, cervix and prostate cancer. In July 2019, his world-leading study TRANSFORM was published in the International Journal of Cancer, evaluating the efficacy of stereotactic radiation therapy for oligometastatic prostate cancer. This Australian study, the world’s largest trial of its kind, was led by Dr Bowden and Icon Cancer Centre experts, with the support of Epworth Medical Foundation and EJ Whitten Foundation. He is currently the Principal or Associate Investigator on a number of major prospective trials, including PINPOINT and PROSPER.
His clinical experience covers a broad range of solid tumour malignancies, with a special clinical interest in urological cancer, gastrointestinal cancer, central nervous system (CNS) and metastatic cancers.